OMERS ADMINISTRATION Corp Invests $5.10 Million in Illumina, Inc. $ILMN

OMERS ADMINISTRATION Corp purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 28,992 shares of the life sciences company’s stock, valued at approximately $5,098,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Osmosis Investment Management UK Ltd acquired a new position in shares of Illumina in the 2nd quarter valued at $925,000. Sanctuary Advisors LLC bought a new stake in shares of Illumina in the 2nd quarter valued at $3,403,000. Biondo Investment Advisors LLC acquired a new stake in Illumina during the 2nd quarter worth $1,869,000. Meiji Yasuda Asset Management Co Ltd. bought a new stake in Illumina during the 2nd quarter worth approximately $860,000. Finally, Clear Harbor Asset Management LLC acquired a new stake in Illumina during the 2nd quarter worth approximately $1,210,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group lifted their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a report on Monday, August 3rd. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. TD Cowen boosted their price objective on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Finally, Barclays boosted their target price on shares of Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $188.40.

Insider Buying and Selling

In related news, CAO Scott D. Ericksen sold 1,500 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total transaction of $225,150.00. Following the transaction, the chief accounting officer owned 14,946 shares in the company, valued at $2,243,394.60. The trade was a 9.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,095,958 shares of company stock valued at $401,720,974 over the last ninety days. 2.90% of the stock is owned by company insiders.

Illumina Stock Performance

Illumina stock opened at $223.22 on Tuesday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $223.97. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The business’s 50-day moving average price is $189.13 and its two-hundred day moving average price is $153.14. The stock has a market cap of $33.71 billion, a PE ratio of 41.65, a P/E/G ratio of 3.09 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.